Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service

GenScript ProBio and Comprehensive Cell Solutions, a Business Unit of the New York Blood Center Enterprises, Form a Pioneering Partnership to Expedite Cell and Gene Therapy Development and Manufacturing

GenScript ProBio, a global contract development and manufacturing organization, and Comprehensive Cell Solutions (CCS), a leader in cell therapy development and manufacturing, have partnered to spearhead the development of cell and gene therapies, offering a unique and seamlessly integrated solution that spans cell collections and apheresis through cryopreservation of final therapeutics.

The partnership's core goal is to accelerate the development of groundbreaking therapies and ensure these transformative therapies are affordable and accessible to the patients who need them. GenScript ProBio and CCS aim to provide pharmaceutical, biotech, hospital, and government entities with a comprehensive suite of cell therapy services. These all-encompassing solutions will help drug developers navigate the intricate challenges of regulatory compliance, cost-effectiveness, quality assurance, and production scalability.

This alliance exemplifies how the proximity of world-class experts, clinicians, and patients to manufacturing specialists and facilities in cell and gene therapies can accelerate and simplify the development and delivery of groundbreaking treatments to patients, starting from conceptualization to commercialization. The initial focus of the collaboration will concentrate on aiding drug developers in advancing cell and gene therapies (CGT) to treat a wide range of indications, including blood cancers, immune disorders, and rare diseases utilizing pioneering modalities including, but not limited to, CAR-T therapies, viral vectors (AAV, LVV, RV, HSV), antibodies (mAb, bsAb, ADC), and vaccines (DNA, mRNA, protein).

The agreement will provide GenScript ProBio with CCS's expertise in clinical cell therapy manufacturing and bone marrow transplant services, along with access to blood-related products, apheresis and cell sourcing, process development and optimization, analytical testing, cryopreservation, and fill/finish. In return, CCS will be able to leverage GenScript ProBio's extensive capabilities in developing and manufacturing antibody/protein drugs, plasmids, viral vectors, vaccines, mRNA, and antibody-drug conjugates.

"We're excited to launch a partnership with GenScript ProBio which expands each of our respective portfolios, and together enables us to support an underserved market of early-stage developers of advanced therapies. With this collaboration, we will streamline and improve the CGT supply chain with continuity and consistency our clients can rely on. This unique one-stop-shop approach accelerates the journey from development to clinic and commercial supply, ultimately improving the lives of patients," said Tracy Kinjerski, Vice President and General Manager of Comprehensive Cell Solutions.

"Joining forces with New York Blood Center's Comprehensive Cell Solutions allows us to harness the combined experience and capabilities of both entities to propel innovation and uphold excellence within the cell therapy sector. Our mutual dedication to quality, safety, and efficiency will expedite the development and commercialization of novel cell therapy treatments for patients," said Patrick Liu, Ph.D., Chairman of the Board of Directors at GenScript ProBio.

In this strategic alliance, GenScript ProBio and CCS will cooperate in various areas, including technology transfer, process development, clinical manufacturing, regulatory strategy, and commercial manufacturing of cell therapy drug products.

The joint effort of GenScript ProBio and CCS signifies a major leap forward in addressing existing challenges in the cell therapy industry. This alliance underscores the immense possibility that lies in working together to bring transformative therapies to market.

For business inquiries, please contact both: Tracy Kinjerski at tkinjerski@nybc.org and Fay Guan at fay.guan@genscriptprobio.com.

About Comprehensive Cell Solutions, a Business Unit of New York Blood Center Enterprises

Arising from New York Blood Center Enterprise's mission to advance the life sciences, Comprehensive Cell Solutions (CCS) is a full-service development and manufacturing organization offering cell sourcing, process development, cryopreservation, cGMP, and fill/finish? for cell, gene, and regenerative therapies. CCS serves academic, emerging biotech, and pharma clients, solving their unique manufacturing challenges with access to quality cellular starting material, R&D support, and technical expertise.

For more information, please visit www.comprehensivecellsolutions.com.

About GenScript ProBio

GenScript ProBio, a subsidiary of GenScript Biotech Corporation, offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, vaccine and antibody protein drug, aiming to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, and China (Hong Kong, Shanghai, and Nanjing) and other regions to serve global customers, and has helped customers in the United States, Europe, Asia Pacific and other regions obtain more than 50 IND approvals since October 2017.

For more information, please visit www.genscriptprobio.com.

These press releases may also interest you

at 19:16
Numinus Wellness Inc. ("Numinus" or the "Company") , is pleased to announce that it has established an at-the-market equity offering program (the "ATM Program") that allows the Company to issue and sell up to C$10,000,000 of common shares in the...

at 19:15
The Cardiovascular Information System (CVIS) Market size is projected to grow by USD 582.77 million, accelerating at a CAGR of 8.8% during the forecast period. Companies are implementing various strategies like forming partnerships, mergers,...

at 19:00
Texas Vein & Wellness Institute (TXVWI), a leading provider of vein and vascular care in the Houston area, is proud to announce its recent accreditation for Peripheral Arterial Interventions and Deep Venous by the Intersocietal Accreditation...

at 17:45
The "Magnetic Stirrer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global magnetic stirrer market has been on a steady growth trajectory,...

at 17:15
Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, today announced the approval of Evkeeza® (evinacumab) in Canada. Evkeeza® was...

at 17:15
The Electrophysiology Catheters Market size is expected to grow by USD 2.24 billion, accelerating at a CAGR of 8.73% during the forecast period, according to Technavio Research. Companies are implementing various strategies like forming partnerships,...

News published on and distributed by: